British American Tobacco set for faster growth as smokeless bet pays off, says Jefferies

Jefferies reiterated a buy rating on British American Tobacco with a 5,500p price target, arguing the company is at an inflection point. The broker expects smokeless next-generation products to generate roughly half of the group's medium-term revenue growth, supporting years of accelerating growth.

Analysis

The investable question is not category growth but whether BTI can convert it into a durable valuation rerating. A sustained improvement in new-category gross margin would reduce the market's concern that BTI is buying revenue through promotion and price competition; that matters because BTI's discount to Philip Morris (PM) is driven as much by execution credibility and regulatory risk as by growth. The highest operational leverage sits in U.S. vapor and oral nicotine, where legal-market share gains can simultaneously support mix, reduce impairment risk, and improve cash conversion.

The principal near-term risk is that legal manufacturers remain disadvantaged by illicit disposable-vape distribution. Aggressive FDA enforcement could be a positive catalyst for BTI's authorized products, but a broad flavor restriction, delayed authorizations, or excise-tax escalation would instead compress category economics and favor incumbent combustible cash flows. Over the next 1-3 months, the market will focus on whether management's next trading update shows accelerating new-category revenue without incremental margin dilution; over 6-18 months, evidence that new-category profit contribution is self-funding is required for a multiple expansion.

Consensus may be underestimating the asymmetry in regulatory normalization: removal of illicit supply would not merely lift BTI volumes, but could lower customer-acquisition spending and improve retailer inventory quality. Conversely, the bullish case is overdone if growth is concentrated in lower-margin geographies or is offset by faster-than-expected cigarette downtrading. This is a BTI-specific thesis; JEF has no meaningful read-through beyond modest capital-markets activity.

Key Decisions for Investors

• Build a 6-12 month long BTI position in tranches, with the second tranche contingent on reported new-category revenue growth accelerating while segment profitability improves. The upside is a rerating toward PM-like credibility if cash conversion follows; exit or reduce if management again defers the path to new-category profitability.
• Use a relative-value expression: long BTI / short MO over 6 months, sized beta-neutral. BTI offers greater upside to international vapor/oral-nicotine normalization, while MO remains more exposed to a slower U.S. combustible pool; close the spread if BTI's U.S. legal-category share fails to improve in the next two reporting periods.
• Set an FDA-enforcement alert rather than pre-buying optionality: initiate incremental BTI exposure following verifiable actions that remove major illicit disposable-vape brands from retail channels. The missing data are enforcement scope, retailer compliance, and BTI's resulting legal-market share; absent these, the broker-driven move alone is not a catalyst.
• Monitor PM and Swedish Match/ZYN retail-share data as the key competitive falsifier. If PM continues to take disproportionate oral-nicotine share while BTI increases promotional spend, BTI's apparent growth will likely be margin-destructive and the long thesis should be reassessed.